Clinical Trial Update: Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.

View source ↗

Summary

A completed clinical trial assessing controlled ovarian stimulation with HP-hMG in IVF/ICSI cycles focusing on ovarian hyperstimulation syndrome in women aged 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• HP-hMG (human menopausal gonadotropin, highly purified)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Ovarian Hyperstimulation Syndrome (OHSS) | Status: COMPLETED